• Navigating the Art of Antibody Formulation with Biopharma Group's CDMO Expertise

Laboratory Products

Navigating the Art of Antibody Formulation with Biopharma Group's CDMO Expertise

Apr 02 2024

The biopharmaceutical landscape is flourishing, with antibody-based therapeutics at the forefront of innovation. However, successfully translating promising discoveries into marketable drugs hinges on a critical step: robust antibody formulation development. At Biopharma Group, our Contract Development and Manufacturing Organization (CDMO) division empowers your R&D team to navigate the complexities of antibody formulation, ensuring a smooth transition from R&D to commercialization.

Biopharma Group’s team of formulation experts understands the intricacies involved in creating a stable and efficacious antibody formulation. Key considerations include:

  • Achieving Long-Term Stability: Guaranteeing the long-term stability of your antibody formulation is crucial. Our scientists employ a deep understanding of factors like protein aggregation and chemical degradation to design formulations that maintain their potency and efficacy over extended periods.
  • Selecting the Right Buffers and Excipients: Choosing the appropriate buffers and excipients is paramount for optimal protein stability and functionality. Biopharma Group's expertise lies in selecting the most compatible excipients and buffer systems to ensure your antibody formulation performs as intended.
  • Scaling Up from R&D to Commercial Manufacturing: The transition from R&D-scale to large-scale manufacturing can introduce unforeseen challenges. Our team's experience in process development and scale-up ensures a seamless transfer, maintaining formulation consistency and quality throughout the process.
  • Precise pH Control: Maintaining the optimal pH level is vital for antibody stability and activity. Biopharma Group's formulation specialists leverage their knowledge to design formulations that achieve and maintain the desired pH throughout the product's shelf life.
  • Ensuring Purity and Activity: High levels of purity and antibody activity are essential for a safe and efficacious drug. Our team implements meticulous purification techniques and activity assays to guarantee your antibody formulation meets the strictest quality standards.

By partnering with Biopharma Group's CDMO division, you gain access to a team of formulation development specialists who can help you overcome these hurdles and achieve a successful antibody formulation. We offer a comprehensive suite of services, from early-stage formulation design to late-stage scale-up and commercial manufacturing.

To learn more about how Biopharma Group's CDMO expertise can expedite your antibody development journey, contact the team today.

Digital Edition

Lab Asia 31.2 April 2024

April 2024

In This Edition Chromatography Articles - Approaches to troubleshooting an SPE method for the analysis of oligonucleotides (pt i) - High-precision liquid flow processes demand full fluidic c...

View all digital editions


Expomed Eurasia

Apr 25 2024 Istanbul, Turkey

AOCS Annual Meeting & Expo

Apr 28 2024 Montreal, Quebec, Canada

SETAC Europe

May 05 2024 Seville, Spain

InformEx Zone at CPhl North America

May 07 2024 Pennsylvania, PA, USA

ISHM 2024

May 14 2024 Oklahoma City, OK, USA

View all events